Active	Status	Sponsor type	Region	Phase	Filter
12 Active 0 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
RX208 / Suzhou NeuPharma, Fosun Pharma
NCT05092802: The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment	Recruiting	2	40	RoW	HLX208	Shanghai Henlius Biotech	Brain Tumor, Primary	05/23	05/24
NCT05065398: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation	Recruiting	2	20	RoW	HLX208	Shanghai Henlius Biotech	NSCLC	06/23	12/23
NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation	Recruiting	2	30	RoW	HLX208	Shanghai Henlius Biotech	Advanced Melanoma	08/23	08/24
NCT05127759: The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation	Active, not recruiting	2	25	RoW	HLX208, BRAF V600E inhibitor	Shanghai Henlius Biotech	Metastatic Colorectal Cancer, mCRC	01/24	06/25
NCT04984369: The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment	Active, not recruiting	2	50	RoW	HLX208, BRAF V600E inhibitor, Cetuximab Injection [Erbitux]	Shanghai Henlius Biotech	CRC	06/24	01/25
NCT05092815: The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation	Active, not recruiting	2	25	RoW	HLX208, BRAF V600E inhibitor	Shanghai Henlius Biotech	Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH, ECD	06/24	10/24
NCT05528406: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation	Not yet recruiting	2	30	NA	HLX208	Shanghai Henlius Biotech	Solid Tumor	10/24	06/25
NCT05102292: The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation	Active, not recruiting	1/2	25	RoW	HLX208, BRAF V600E inhibitor	Shanghai Henlius Biotech	Anaplastic Thyroid Cancer, ATC	06/24	12/24
NCT05641493: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation	Recruiting	1/2	49	RoW	HLX208+HLX10	Shanghai Henlius Biotech	Non Small Cell Lung Cancer	03/25	02/26
NCT05902728: Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects	Completed	1	20	RoW	HLX208, Itraconazole 200 mg, Rifampicin	Shanghai Henlius Biotech	NSCLC	12/23	12/23
NCT05841940: Mass Balance Study of [14C]HLX208 in China Healthy Subjects	Completed	1	6	RoW	[14C]HLX208	Shanghai Henlius Biotech	Mass Balance Study in Healthy Subjects	07/23	12/23
NCT04965220: HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors	Recruiting	1	220	RoW	HLX 208, trametinib	Shanghai Henlius Biotech	Solid Tumor	06/24	06/25